Clinical studies with dopamine-receptor stimulants.
Oral administration of ET-495 was found to cause worsening of psychiatric status in 4 out of 7 schizophrenic patients, and to induce a paranoid state and a syndrome of auditory hallucinosis in 2 non-schizophrenics. These observations were compatible with the hypothesized role of dopamine in schizophrenia. However, these psychotogenic effects were far less dramatic than those noted in other studies with amphetamine, methylphenidate or L-Dopa. Possible explanations for this differing psychotogenic potency of receptor stimulators versus presynaptic agonists are presented. Intravenous ET-495 and apomorphine did not show psychotogenic effects.
D000328:Adult; D001058:Apomorphine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D010891:Piribedil / Q000494:pharmacology*; D011955:Receptors, Drug / Q000187:drug effects; D012559:Schizophrenia / Q000378:metabolism*; D012563:Schizophrenia, Paranoid / Q000139:chemically induced; D012565:Schizophrenic Psychology; D013268:Stimulation, Chemical; D014839:Vomiting / Q000139:chemically induced
D010879:Piperazines; D011955:Receptors, Drug; D010891:Piribedil; D008787:Metoclopramide; D001058:Apomorphine; D004298:Dopamine